Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Tolerability of V503 (Gardasil 9) in Men 16-26 Years
NCT02114385Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2014
- Primary completion
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started Mar 2014; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT02114385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114385.